In vitro activation of cancer patient–derived dendritic cells by tumor cells genetically modified to express CD154
- 11 September 2002
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (10) , 846-853
- https://doi.org/10.1038/sj.cgt.7700507
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunityGene Therapy, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000
- Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte ResponseThe Journal of Experimental Medicine, 1999
- Tumor ImmunologyImmunity, 1998
- Licence to killNature, 1998
- Help for cytotoxic-T-cell responses is mediated by CD40 signallingNature, 1998
- T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactionsNature, 1998
- Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.The Journal of Experimental Medicine, 1996
- Tumor immunotherapy: the tumor cell as an antigen-presenting cellCurrent Opinion in Immunology, 1994